Viagra Super Active

By T. Hassan. Brigham Young University Idaho.

Drug-Drug Interactions JAN THODEN With an increasing number of antiretroviral drugs there is an growing risk of adverse drug-drug interactions cheap viagra super active 50mg with visa erectile dysfunction drugs at walmart. Moreover buy 100mg viagra super active amex erectile dysfunction family doctor, antiretroviral drugs are used by an aging patient population with a variety of co-morbidities requiring additional medications viagra super active 100mg sale erectile dysfunction doctor prescription. By inducing or inhibiting enzyme production, the elimination of a drug and hence its plasma levels are influenced. Especially metabolization by cytochrome-P450 plays a crucial role. As many drugs, PIs and NNRTIs are mainly metabolized by CYP3A4 in liver and the gastrointestinal tract. Another pathway is the glucuronidation by glucuronosyltransferases, though this usually does not cause clinically relevant inter- actions. Moreover, there are major interindividual differences in enzyme activity and drug metabolization rates. Other factors that need to be considered include genetic polymorphisms, ethnicity, age, sex, and co-morbidities. The tables provide a brief overview of drug combinations deemed safe (+) as well as those that should be avoided (L). However, for many combinations the interactions are uncertain, unknown or can only be assumed based on theoretical calculations (K). In these cases, use might still be safe and should be controlled by TDM. The first part is focused on ART/ART interactions, the second part on those between ART and concomitant medications. Among the INSTIs, elvitegravir is listed as the fixdose tablet Stribild (STB). Cobicistat stand-alone (Tybost) which is approved in combinations with atazanavir and darunavir, is not listed, as well as irrelevant drugs such as d4T, ddI indinavir, nelfi- navir. All PIs are assumed to be given boosted with ritonavir or cobicistat. T-20 is only mentioned in the first part as there are no known relevant interactions. This chapter is intended as a tool to support rapid decision making in the daily prac- tice, but should not replace a literature search. On rare occasions, drug combina- tions with known adverse effects might be unavoidable due to a lack of alternatives. In these cases, close monitoring (including TDM) is necessary. Individual questions regarding interactions can be answered by experts (e. Abbreviations: + Combination of these drugs possible K Potential interactions or unknown, combination of these drugs is often possible, therapeutic drug monitoring suggested L Combination of these drugs should be avoided or is contraindicated ↑ up to 50% increased drug levels, ↑↑ up to 100%, ↑↑↑ >100% ↓ up to 50% decreased drug levels, ↓↓ up to 100%, ↓↓↓ >100% BID Twice daily (TID = Three times daily. QD = Once daily) TDM Therapeutic drug monitoring Drug-Drug Interactions 659 Part 1: ART + ART NRTIs + NRTIs 3TC ABC FTC TDF AZT 3TC + L1 + + ABC K + FTC L1 + + + TDF + K + K AZT + + + K 1 Antagonism NRTIs + NNRTIs 3TC ABC FTC TDF AZT EFV + + + + + ETV + + + + + NVP + + + + + RPV + + + + + NRTIs + PIs 3TC ABC FTC TDF AZT ATV + + + K1 + DRV + + + +2 + FPV + + + + + IDV + + + + + LPV + K3 + +2 + NFV + + + + + RTV + + + K + SQV + + + + + TPV + K3 + + K3 1 ATV ↓, TDF ↑, ATV always boosted 2TDF ↑, caveat: combination with nephrotoxic drugs, increased nephrotoxicity possible 3 NRTI ↓ (unknown relevance) NRTIs + EIs/INSTIs 3TC ABC FTC TDF AZT T-20 DTG MVC RAL STB as a single tablet regimen should not be coadministered with other ARTs 660 Drugs NNRTIs + EIs/INSTIs, EIs/INSTIs + EIs/INSTIs EFV ETV NVP RPV T-20 DTG MVC RAL EFV L, NNRTIs + K4 K1 K2 ETV should not + L5 K1 + NVP be combined + L RPV with each other T-20 DTG L4 L5 L4 L MVC K1 K1 3 RAL K2 L +3 1 MVC ↓↓, increase MVC to 2 x 600 mg/d, if not combined with PI or potent CYP3A4 inhibitor 2 RAL ↓, relevance unclear 3 RAL ↓, MVC ↓, probably without clinical rele-vance 4 DTG↓increase DTG to 50mg BID 5 DTG↓no combination with EFV without co-administration of ATV, LPV or DRV STB as a single tablet regimen should not be coadministered with other ARTs NNRTIs + PIs, EIs/INSTIs + PIs EFV ETV NVP RPV T-207 DTG MVC RAL ATV K1 L1 KK+ + K2 K DRV K + + + + + K2 + FPV KL KK3 + K8 + + LPV K4 + K4 K2 + RTV KK+ K + KK2 + SQV K +5 KK+ KK2 + TPV + L6 + KKK8 + K 1 ATV ↓↓, ATV always boosted 2 MVC ↑↑↑, reduce MVC to 2 x 150 mg/d 3 FPV ↑↑, relevance unclear, monitor FPV levels 4 LPV ↓, increase LPV to 2 x 3 tablets (controversial in combination with NVP, use TDM) 5 SQV ↓↓, always boosted 6 ETV ↓↓, TPV↑, combination therefore not recommended 7 T-20 can be increased by PIs, PIs by T-20, too, no clinical relevance; TDM if problems 8 DTG↓, increase DTG to 50 mg BID PIs + PIs ATV DRV FPV LPV RTV SQV TPV ATV + KK 1 L DRV + KL+ LL FPV KK K 2 L LPV KLK L RTV SQV +1 L +2 L TPV LLLL+ L 1 ATV ↑, SQV ↑, combination well tolerated 2 FPV with 200 mg RTV, combination possible Comment: The combination of two PIs is probably not more effective compared to second generation PIs (DRV and TPV) Drug-Drug Interactions 661 Part 2: ART + concomitant medications Gastrointestinal agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Cimetidine K K2 Famotidine K2 Loperamide MCP K Mesalazine K + KK Ondansetrone 1 +1 +1 K Ranitidine K2 PPIs L3 1 NNRTIs are strong enzyme inductors, ondansetrone levels can be decreased 2 RPV should not be coadministered with H2-blocking agents, alternatively H2-blocker >12h before or 4h after RPV. MCP = metoclopramide, PPIs = proton pump inhibitors Antiarrhythmic drugs Most PIs increase the drug levels of antiarrhythmic drugs. In combination with NNRTIs the levels might be fluctuating. Antiarrhythmic drugs should be introduced with the lowest possible dosage. Calcium channel inhibitors will be discussed separately. KKKKKLLLL Lithium Mirtazapine KKKKKKKK1 + Nortriptyline KKKKK Paroxetine KKKKK+1 Sertraline KKKKKK1 Trazodone K1 KK+ Venlafaxine K1 KK+ 1 CNS-effects of EFV can be increased Comment: No data exists for most antidepressants and their interactions with NRTIs. PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Amitriptyline1 LKLKKKKK7 + K Bupropion KKKKKKKK1 7 + K Citalopram4 KKKKKKKK7 + K Desipramine1 KKK+ KKKK7 + K Doxepin4 KKKKKKKK7 + K Fluoxetin4 KKKKKKKK7 + K St. LLLLLLLL Lithium K Mirtazapine KKKKKKKK7 + K Nortriptyline1 KKKKKKKK7 + K Paroxetine K2 K2 K2 L4 K4 K4 KK7 + K Sertaline KK KLKK KK3 4 7 + K Trazodone LL LKLL4 + K7 Venlafaxine5 KKKKKKKK7 1 Tricyclic antidepressants and boosted PIs: PI ↑, antidepressant ↑ 2 Paroxetine ↓–↓↓, adjust if applicable 3 Sertraline ↓, adjust if applicable 4 Antidepressant↑, titrate dose! STB should not be combined with Astemizole and Terfenadine. Potential interactions with other antihistamines, consider Cetirizine. PIs/NNRTIs ATV DRV FPV LPV SQV TPV EFV ETV NVP RPV Astemizole1 LLLLLLLLKK Cetirizine 2 Fexofenadine KKKKKKKKK2 + Loratadine KKKKKKKK Terfenadine1 LLLLLLLLKK 1 Cave at: Arrhythmia 2 CNS-effects of EFV can be increased Comment: No relevant interactions with NRTIs 666 Drugs Antihypertensive therapy Calcium-channel blockers (CCB) can be increased (separate chapter), especially in combination with PIs or STB. In combination with NNRTIs variations in drug levels are possible. The combination of beta blockers and Atazanavir can lead to QT-prolongation. There are interactions between STB and beta blockers, their levels may increase. Anticonvulsants NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Carbamazepine KKKKKK LK L1,2 1 Gabapentine 2 Lamotrigine 2 Levetiracetam L Oxcarbazepine KKL Phenobarbital + K KKLKL Phenytoin + K KKLK+ Pregabaline K + KK+ + + + + Valproic acid + K K3 + + K + 1 EFV ↓, NVP ↓, avoid combination or monitor closely (TDM) 2 CNS-effects of EFV can be increased 3 AZT ↑↑, monitor for side effects PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Carbamazepine K1 K1 K1 K1 K1 K1 KLKK3 Gabapentine + + + + + + + + + + Lamotrigine K 2 Levetiracetam Oxcarbazepine KKKKKK+ KK3 + Phenobarbital KLKKKKKLKK3 Phenytoin KLLKKKKLKK3 Pregabalin Valproic acid K K + KKK+ K 1 PIs ↓, Carbamazepine ↑, avoid if possible or monitor closely (TDM) 2 Lamotrigine ↓, increase if necessary 3 Avoid this combination, DTG↓ Drug-Drug Interactions 667 Anthelmintic agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Albendazole KKKK+ Diethylcarbamazine Ivermectin + + + + + KKK+ Levamisole (Ergamisol) Mebendazole KKKK+ Niclosamide Oxamniquine Praziquantel + + + + + KKK+ Pyrantel Suramin sodium K Triclabendazole + + + + + KKKK PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Albendazole KKKKKK+ K Diethylcarbamazine Ivermectin KKKKKK+ K Levamisole (Ergamisol) Mebendazole KKKKKK+ K Niclosamide Oxamniquine KKK+ KK+ K Praziquantel KKKKKK+ K Pyrantel Suramin sodium Triclabendazole KKKKKKKK 668 Drugs Antimycotic agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Amphoter. B K + KLK1 1,2 Caspofungin KKKKK K1,2 8 K8 K8 + Fluconazole K1,2,3 K4 K Flucytosin K + KKK Itraconazole K6 K5 L4 K Ketoconazole K6 K5 L7 K Posaconazole + K KL K10 5 K4 K Terbinafine KKKKK Voriconazole KKKKKK K6,9 5 K4 K 1 Caveat: additive nephrotoxicity possible 2 Increased hematotoxicity 3 AZT ↑↑, Fluconazole ↓ 4 NVP ↑↑, monitor liver function tests; in combination with azoles Fluconazole still preferred 5 azoles increase ETR levels, relevance unclear 6 NNRTIs ↑, azoles ↓ 7 NVP ↑, Ketoconazole ↓↓ 8 Caspofungin ↓, dose 70mg/d recommended. B KK+ K Caspofungin KKKK+ KK K Fluconazole K1 + K Flucytosine K K Itraconazole2 KKKK3 + KK K4 Ketoconazole2 KK+ K + KK K4 Posaconazole L7 KKKKKKK6 Terbinafine KK+ K Voriconazole5 KLKLKKKK6 1 Fluconazole ↑↑, do not excess 200 mg/d 2 PIs ↑, Itra-/Ketoconazole ↑, avoid doses >200 mg/d 3 LPV ↑, Itraconazole ↑; avoid doses >200 mg Itrac. Calcium channel antagonists (CCB) The serum levels of CCB can be increased, especially if combined with PIs. Lercarnidipine is contraindicated in combination with boosted PIs. In combination with NNRTIs serum levels might be fluctuating. Start CCB at low dose and titrate to full effect, monitor BP or discuss alternatives. Drug-Drug Interactions 669 NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Amlodipine KKK+ Diltiazem KKKK Felodipine KKK+ Lercarnidipine KKK+ Nifedipine KKK+ Verapamil KKKK PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Amlodipine KKKKKKKK+ K Diltiazem KKKKKKKK+ K Felodipine KKKKKK+ K Lercarnidipine LLLLLL+ L Nifedipine KKKKKKKK+ K Verapamil KKKKKKKK+ K Immunosuppressants/Chemotherapeutic agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Azathioprine K1 Carboplatin K + KKK2 1 Ciclosporin KKKKKKK2 3 3 K3 K Cisplatin K + KKK2 1 Cyclophosph. KKKKKKKK1 + Cytarabine K1 Daunorubicin K1 K Docetaxel KKKK Doxorubicine K1 KKK+ Etoposide K1 KKK+ Fluorouracil + KKKK1 Gemcitabine K1 Interferon K1 Interleukin 2 + + + K2 K1 Irinotecan K1 KKK+ Methotrexate5 KKKKK2 1 KKKK Mycophenolat Oxaliplatin Paclitaxel KKKKK1 +4 +4 +4 + 670 Drugs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Sirolimus K3 K3 K3 + Tacrolimus K + KK2 + K3 K3 K3 K Tam oxifen KKK+ Vinblastine K + KKKKKK+ Vincristine K + KKKKKK+ 1 AZT: Hematotoxicity, avoid if possible 2 Additive nephrotoxicity possible 3Immunosuppressants ↑–↓, always TDM and dose adjustments! PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Azathioprin Carboplatin Ciclosporin1 KKLKKKKK Cisplatin K Cyclophosph. KK+ K Cytarabine Daunorubicin K KL K6 Docetaxel KKKKKKKK Doxorubicine K3 K3 K3 K3 K3 + K K Etoposide K3 K3 K3 K3 K3 K3 KK+ K Fluorouracil Gemcitabine Interferon Interleukin 2 K Irinotecan L2 K2 K2 K2 K2 K4 + K Methotrexate6 KKKKKKKKKK Mycophenol. TDM of MMF recommended Drug-Drug Interactions 671 Contraception The serum levels of both ethinylestradiol and norethindrone can be very fluctua- tion especially in combination with (boosted) PIs. Therefore the use of oral contra- ceptives containing these hormones might be unsafe. Furthermore their levels can be fluctuating if combined with efavirenz and nevirapine.

In 2 fair-quality trials of aripiprazole 2 mg discount 25mg viagra super active fast delivery erectile dysfunction treatment pumps, improvements were not 488 order viagra super active 100mg on line impotence cure food, 489 489 better than placebo on most outcomes generic 25mg viagra super active testosterone associations with erectile dysfunction diabetes and the metabolic syndrome. In 1 of these, aripiprazole 10 mg was significantly better than placebo on the NPI-NH, BPRS total, BPRS core, CMAI, and CGI-S. The 5 mg dose of aripiprazole had mixed results, with improvement seen on some secondary outcomes. A flexibly-dosed trial of aripiprazole, with doses ranging from 0. A good-quality trial of olanzapine 5 mg or 10 mg found improvement at 6 weeks on the 492 NPI-NH and BPRS, but a second, fair-quality trial showed no difference at any dose (1 mg, 2. In 2 placebo-controlled trials, immediate-release quetiapine was no different from placebo on the CMAI. One of these trials found improvement for immediate-release quetiapine on the Severe Impairment Battery. The other found no difference from placebo on the primary outcome measure, the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC), using a last observation carried forward (LOCF) analysis. There was improvement in the immediate-release quetiapine group on the CGI-C but no difference from placebo on the NPI- NH or the CMAI. Two found efficacy for risperidone on the BEHAVE-AD and 1 found no difference. Placebo-controlled trials of atypical antipsychotics in patients with behavioral and psychological symptoms of dementia Study, Year Medications compared (quality) (mean daily dose) N Duration Main efficacy results No difference from placebo on NPI Total or Psychosis scores, CGI-S or CGI-I. Aripiprazole superior to placebo on BPRS de Deyn, Aripiprazole 2 mg Psychosis and Core scores, no difference 2005 208 10 weeks Placebo from placebo in BPRS Total score at (fair) endpoint (although superior to placebo at week 6) Aripiprazole 10 mg: superior to placebo on NPI-NH, BPRS Total, BPRS Core, CMAI, Aripiprazole 2 mg and CGI-S. Mintzer, Aripiprazole 5 mg Aripiprazole 5 mg: superior to placebo on 2007 487 10 weeks Aripiprazole 10 mg BPRS Core, CMAI, but not CGI-I. No difference between groups on NPI-NH Psychosis scale or CGI-S (primary endpoints) Streim, Aripiprazole 9 mg (range Secondary outcomes: 2008 0. No difference from placebo on BPRS Atypical antipsychotic drugs Page 120 of 230 Final Report Update 3 Drug Effectiveness Review Project Study, Year Medications compared (quality) (mean daily dose) N Duration Main efficacy results Psychosis, BPRS Core, NPI-NH Psychosis Care Distress, MMSE, or NPI- NH Psychosis response rate Street, Olanzapine 5 mg Olanzapine superior to placebo on NPI- 2000 Olanzapine 10 mg 206 6 weeks NH and BPRS (good) Placebo Olanzapine 1 mg Mixed results: de Deyn, Olanzapine 2. Intramuscular short-acting Meehan, Significant effect compared with placebo; olanzapine 2002 272 24 hours no difference between olanzapine and Lorazepam 1 mg (fair) lorazepam. Placebo No difference compared with placebo on Ballard, Quetiapine IR CMAI. No difference compared with placebo on Zhong, Quetiapine IR 100 mg primary outcome measure PANSS-EC. Brodaty, Risperidone superior to placebo on CMAI Risperidone 2003 309 12 weeks (total and 4 of 5 subscales) and BEHAVE- Placebo (fair) AD (total and 5 of 7 subscales) Risperidone 0. Mintzer, Risperidone No difference compared with placebo on 2006 473 8 weeks Placebo BEHAVE-AD or CGI-C (fair) Abbreviations: IR, immediate release. Because they differed in their outcome measures and other factors these trials did not provide indirect evidence for comparative efficacy among the atypical antipsychotics. There was no difference between olanzapine 406 and lorazepam in 1 of these trials. Harms The following text focuses on withdrawals and adverse events related to tolerability. For information on evidence related to mortality and cerebrovascular adverse events in patients with behavioral and psychological symptoms of dementia, see the Serious Harms section. Atypical antipsychotic drugs Page 121 of 230 Final Report Update 3 Drug Effectiveness Review Project Direct evidence Withdrawals and adverse events reported in head-to-head trials of atypical antipsychotics are shown in Evidence Table 13 and Table 26, below. In the CATIE-AD trial, there was no difference between active treatment groups or between any treatment group and placebo in 468 overall withdrawals. All treatment groups had higher rates of withdrawals due to intolerability, adverse events, or death compared with placebo, but there was no difference between treatment groups for this outcome. One trial found a higher rate of withdrawals due to adverse events with 474 olanzapine (16. No other differences in withdrawal rates were identified in head-to-head trials. In the CATIE-AD trial, the incidence of extrapyramidal symptoms or Parkinsonism was higher in the olanzapine and risperidone groups (12% in each) than in the immediate-release quetiapine (2%) and placebo (1%) groups (P<0. In another head-to-head trial of immediate- 475 release quetiapine and risperidone, there were no significant differences between groups in extrapyramidal side effects as measured by the Simpson-Angus scale. In this trial, the mean daily dose of immediate-release quetiapine was 77 mg, whereas it was somewhat lower in the CATIE- AD trial (56. The risperidone doses in these trials were similar (1. Four trials other than CATIE-AD looked at the incidence of extrapyramidal side effects with olanzapine compared with risperidone, and most found similar rates between groups. The exception was a trial in which the risperidone group showed more increase from baseline on SAS 474 than the olanzapine group. In this same trial, however, there was no difference between olanzapine and risperidone on the Abnormal Involuntary Movement Scale (AIMS) or the Barnes Akathisia Rating Scale (BARS). A recent analysis of CATIE-AD found that duration of antipsychotic use was significantly associated with weight gain in women but not men. A similar pattern was seen for body mass index, with increases in women but not men. Results for the individual atypical antipsychotics are not reported separately for men and women; overall, there was significant average weekly weight gain in the olanzapine (P=0. There was also a trend for weight gain in the risperidone group, but it was not statistically significant (P=0. Additionally, olanzapine treatment was associated with increased waist circumference and decreased high-density lipoprotein 500 cholesterol. Atypical antipsychotic drugs Page 122 of 230 Final Report Update 3 Drug Effectiveness Review Project Table 26. Adverse events in head-to-head trials of atypical antipsychotics in patients with behavioral and psychological symptoms of dementia Medications Study, compared Withdrawals due Year, (mean daily Withdrawals to adverse Duration dose) overall events Extrapyramidal symptoms Incidence of parkinsonism or All groups extrapyramidal side effects significantly Overall P=0. Overall withdrawal rates were high in short-term trials, ranging from 20% to 34% in olanzapine groups, 3% to 42% in risperidone groups, and 7% to 30% in haloperidol groups. Placebo withdrawal rates were also high, ranging from 23% to 35%. Subgroups No study reported separate analyses by demographics or comorbidities. The majority of subjects in dementia trials were frail, elderly residents of nursing homes. In 1 study comparing 484 risperidone with haloperidol conducted in Hong Kong, all patients were of Chinese ancestry. It was not possible to make conclusions about comparative efficacy in different ethnic groups from these studies. More subjects were female in all of these studies, reflecting the overall population of elderly patients with dementia.

Antiepileptic drugs Page 38 of 117 Final Report Update 2 Drug Effectiveness Review Project Table 7 purchase viagra super active 25 mg otc impotence vacuum pump. Pooled results of antiepileptic drugs compared with placebo for reduction of migraine frequency (Chronicle 2004) Antiepileptic Reduction in migraine Proportion with ≥50% reduction agent frequency per month in migraine frequency N N studies/ studies/ subjects SMD (random) buy viagra super active 50mg free shipping erectile dysfunction las vegas, 95% CI subjects Odds ratio (95% CI) Divalproex sodium --- --- 4/574 3 viagra super active 50mg sale erectile dysfunction treatment in kl. Many of the included trials studied various doses of antiepileptic drugs (Table 8). Chronicle and colleagues assessed the impact of various doses for valproate and topiramate. No clear dose-response was found for the drugs, although the 50 mg/d dose of topiramate resulted in the lowest standardized mean difference in migraine frequency among topiramate doses (50, 100, or 200 mg/d). However, the number of studies in these analyses was few, and the resulting confidence intervals were wide, such that these findings should be used with caution. Also, many of the active-control trials used dose comparisons that could be considered unequal. Studied doses of antiepileptic drugs for migraine prophylaxis Antiepileptic drug Daily dose (mg/d) Carbamazepine Not reported Sodium valproate 400 – 1500 Divalproex sodium 500 – 1500 Gabapentin 1200 – 2400 Lamotrigine 50 – 200 Oxcarbazepine 1200 Additional trials 109 110 We identified 10 trials not included in the Chronicle review: 1 valproate, 1 carbamazepine, 111-117 113 7 topiramate (including 1 trial with lamotrigine and placebo comparisons), and 1 118 110 oxcarbazepine. The carbamazepine trial was rated as having poor internal validity due to inadequate randomization, allocation, and blinding, and lack of an intention-to-treat analysis. The results from these trials will be discussed briefly here. We also independently evaluated all trials for quality-of-life information. Direct comparisons of antiepileptic drugs 113, 119 We identified 2 trials directly comparing one antiepileptic drug with another. In 2 small (N=60 and N=64) crossover studies topiramate was compared with lamotrigine, and topiramate was compared with valproate and placebo. At the end of 20 weeks, a larger portion of the topiramate group than the placebo group achieved ≥50% reduction in migraine frequency (63% compared with 30%; 95% CI, 0. Similar to the findings of Chronicle, there was no statistically significant difference in the proportion of patients with ≥50% reduction in migraine frequency for lamotrigine compared with placebo (46% compared with 34%; 95% CI, 0. However, when topiramate was compared with lamotrigine, more patients had a response with topiramate than with lamotrigine, although the confidence interval was wide (63% 113 compared with 46%; 95% CI, 3% to 31%). In the direct comparison of valproate and topiramate, analysis of the first drug assigned found no statistically significant difference in headache frequency, but topiramate was better at reducing headache intensity (mean difference on 10-point visual analog scale 2. In analysis of the second randomized period, topiramate was superior in reducing the number of headaches (mean difference 1. Using ANOVA to analyze the first and second randomized periods combined, the authors found no statistically significant differences. However, the conflicting findings of the first and second periods raises the question of carryover effects, such that data from the first period is preferred. Comparisons with placebo For topiramate, 2 studies published since the Chronicle review reported conflicting findings: The larger study was unable to find a statistically significant difference compared with placebo, while 113, 115 the smaller study did. Pooling these studies with the previous studies indicates a statistically significant benefit of topiramate (odds ratio 3. This compares with the pooled odds ratio for topiramate compared with placebo reported by Chronicle of 3. The mean change in migraine frequency was quite different in the 2 trials, and inadequate data were reported to allow pooling with the previously reported studies (see Table 9). Topiramate compared with placebo for prophylaxis of migraine Reduction in mean number of Proportion of group with ≥50% migraines per month reduction in migraine Trial N (change from baseline) frequency Silberstein -1. No additional placebo-controlled trials were identified for carbamazepine, valproate, or gabapentin. One new active-control trial that compared valproate with subcutaneous histamine was 109 identified. No significant difference in treatment effect for lowering migraine frequency or MIDAS scores was observed in 92 adults randomized to valproate or subcutaneous histamine injection at the end of 12 weeks. Quality-of-life and disability outcomes 120- Among all studies from the Chronicle review and an updated search, only 3 topiramate trials 122 118 and 1 oxcarbazepine trial assessed quality-of-life outcomes. There were no significant differences between oxcarbazepine-treated and placebo-treated patients in improvement of 118 120, 122 quality-of-life scores using the SF-36 assessment tool. In 2 trials of 937 adults , patients treated with topiramate 50-200 mg reported significantly better improvement in the performance of daily activities limited by migraine headaches per MSQ-RR than patients treated with placebo. Similar findings were observed with MSQ-RP scores as well. Topiramate more greatly reduced the number of disability days due to headache than 121 placebo. Baseline mean days with disability was approximately 7. At the end of 16 weeks, the reduction in disability days was significant for topiramate and not placebo (change from baseline -4. Topiramate cessation compared with continuation 112 One new topiramate trial compared cessation with continued therapy in a study that began with a 26-week open-label phase and followed with a 26-week double-blind phase. Of 818 adults enrolled in the open-label phase using topiramate, 63% remained and were randomized to continue with topiramate or switch to placebo in the double-blind phase. The primary objective was to evaluate rebound effect after discontinuation of migraine prophylaxis by comparing the number of migraine days during the last month of the double-blind phase with the number of migraine days in the last month of the open-label phase. Patients who switched from topiramate to placebo after 26 weeks experienced an increase in the number of migraine days in a month by 1. In contrast, patients who continued topiramate experienced minimal change in migraine days (+0. Despite worsening control of migraines, the number of migraine days in the placebo group during the last month of the double-blind phase (5. Chronic migraine Chronicle and colleagues excluded chronic migraine studies from their review due to concerns with significant differences in disease severity relative to patients without chronic migraines. We 114, 116, 117 111 identified 3 placebo-controlled trials of topiramate and 1 head-to-head trial evaluating topiramate and valproate and decided to review the results independently and assess whether the results were significantly different between those with and without chronic migraine. A small (N=49), open-label, active-control trial comparing topiramate 75 mg/d with divalproex sodium 750 mg/d found that at the end of 12 weeks, topiramate-treated and valproex- treated patients exhibited similar reductions in headache frequency (change from baseline, -23. The results from this poor-quality study should be considered with caution since about 10% of the population were not included in the analyses. Two placebo- controlled trials showed topiramate was more effective than placebo in reducing migraine 116, 117 116 frequency and monthly migraine days. In a study of 306 adults the change in mean monthly migraine days for topiramate was -6. An additional 121 trial showed similar findings but was rated poor. Although the collective result shows that topiramate is more effective than placebo, it is unclear whether the findings in patients with chronic migraine headache should be combined with results in patients without chronic headaches. Chronic pain Very little evidence was found to support the short-term use of tiagabine, topiramate, or 123-125 gabapentin for treatment of chronic pain conditions. No evidence was found for other antiepileptic drugs. Open-label tiagabine and gabapentin were directly compared in 91 patients with various 125 types of chronic pain despite ongoing treatment with analgesics or antidepressants.

Antiviral efficacy is higher than with valacyclovir or famciclovir (Cattamanchi 2011) purchase viagra super active 50mg with mastercard erectile dysfunction symptoms. However 50mg viagra super active free shipping erectile dysfunction 19 year old male, there are no data on clinical efficacy in AIDS-related KS published to date discount 50 mg viagra super active with visa jack3d causes erectile dysfunction. As HHV-8 is involved in the early steps of KS pathogenesis, it is questionable if valganciclovir has any effect on manifest lesions. In patients with classical KS, the drug remained inefficient (Krown 2011). Good response rates in uncon- trolled studies on HIV-negative renal transplant recipients with KS (Stallone 2005, Campistol 2007). It is postulated that these drugs inhibit tumour angiogenesis through impaired vascular endothelium growth factor production. A study of combination with liposomal doxorubicine is ongoing. In a Phase II study, treatment with imatinib mesylate yielded to partial regression in 33% of AIDS/KS cases (Koon 2013). MMP inhibitors such as COL-3 have shown activity in a Phase II study on patients with advanced KS (Dezube 2006). However, clinical response rates were at best moderate. The most common adverse events were photosensitivity and rash. Encouraging Phase II study with topical halofuginone (Koon 2011). Many studies on different formulations have been conducted (Duvic 2000, Bodsworth 2001, Bernstein 2002, Aboulafia 2003). Retinoids will probably face a difficult path in attaining approval for KS. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune recon- stitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Blood 2004; 104: 810-4 Ardavanis A, Doufexis D, Kountourakis P, Rigatos G. A Kaposi’s sarcoma complete clinical response after sorafenib administration. Docetaxel in anthracycline-pretreated AIDS-related Kaposi’s sarcoma: a retrospective study. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome- associated Kaposi’s sarcoma. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. Brambilla L, Tourlaki A, Ferrucci S, Brambati M, Boneschi V. Treatment of classic Kaposi’s sarcoma-associated lym- phedema with elastic stockings. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Kaposi’s sarcoma in renal transplant recipients—the impact of proliferation signal inhibitors. Cellular origin of Kaposi’s sarcoma and Kaposi’s sarcoma-associated herpesvirus- induced cell reprogramming. Valganciclovir for suppression of human herpesvirus-8 replication: a ran- domized, double-blind, placebo-controlled, crossover trial. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. Long-term clinical outcome of AIDS-related Kaposi’s sarcoma during highly active antiretroviral therapy. Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Antiproliferative effect of retinoid compounds on Kaposi’s sarcoma cells. Crane HM, Deubner H, Huang JC, Swanson PE, Harrington RD. Fatal Kaposi’s sarcoma-associated immune recon- stitution following HAART initiation. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS Malignancy Consortium Study. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi’s sarcoma: a systematic review. Radiation therapy in the treatment of HIV-related Kaposi’s sarcoma. Looking for the target cell of Kaposi’s sarcoma-associated herpesvirus. Topical treatment of cutaneous lesions of acquired immunodefi- ciency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study.

N=417; Mean 67 ±5 years; (replaced once/week) Between group difference at 2 years: 2 discount viagra super active 50 mg erectile dysfunction photos. Hormone therapy Page 45 of 110 Final Report Update 3 Drug Effectiveness Review Project Study Design; Study/year Number; Population (quality) Duration characteristics Interventions Main outcomes/results Estradiol patch/levonorgestrel Warming discount 100mg viagra super active overnight delivery erectile dysfunction age 80, Double-blind Postmenopausal purchase viagra super active 50mg fast delivery sublingual erectile dysfunction pills, 45 micrograms estradiol Difference in BMD, HRT vs. One trial did not report treatment and placebo group differences, but stated that forearm bone density in the treatment group was statistically 125 significantly increased from baseline while the placebo group showed no change. Another trial reported a trend in E2 groups towards increased bone density, however statistical 126 significance was not reached for between group comparisons. All 15 trials of transdermal E2 reported statistically significant improvements in bone 127-139 density compared to placebo. Only three trials did not use concomitant 129, 134, 138, 140, 141 progestin/progesterone. Five trials of E2V with concomitant progestin/progesterone reported bone density 111, 142-145 outcomes. Four of the five trials noted improvement in treatment groups compared to 111, 142-144 145 placebo, and one did not. All trials reported significant within-group changes in bone density at multiple sites for various doses with higher doses showing greater changes. In a good-quality trial comparing combination treatment with CEE (with or without medroxyprogesterone) plus alendronate to either treatment alone, patients on combination therapy had a significantly greater increase in total hip BMD than those 170, 171 151 on either ALN or HRT alone after 3 years (p<. A more recent substudy of the Women’s HOPE trial found that most women on lower doses of CE with or without medroxyprogesterone (0. Similar improvements were found in the lumbar spine. In subjects with 6-year follow-up BMD data (n=443), the percentage increase in lumbar spine BMD was 7. The CEE-only study of the WHI produced modest but consistent positive effects on bone 173 mineral density. Hormone therapy Page 46 of 110 Final Report Update 3 Drug Effectiveness Review Project 174 One study of esterified estrogen examined dosages of 0. Effect of discontinuation of estrogen on bone density Two studies reported the effect on bone density after discontinuing the use of estrogen to determine if bone density gains were sustained after discontinuation, or if there was evidence that bone loss was accelerated in women who had used estrogen therapy when compared with 175, 176 those who had not used it. Both studies found the rate of bone loss after stopping estrogen was similar to that of women who did not receive estrogen treatment, as described below. Further bone density gains were not observed in women after discontinuation of estrogen therapy, but there was also no evidence of accelerated bone loss when compared with those who had taken placebo. The second study reported the effect on bone mineral density of discontinuation of estrogen therapy for one year after 5 years of treatment in women enrolled in a randomized placebo-controlled trial of raloxifene and estrogen for 176 prevention of postmenopausal bone loss. This study also found that changes in bone density after one year of discontinuation were not significantly different in women using CEE compared with women randomized to placebo. Comparison with other meta-analyses A Cochrane review and meta-analysis published in 2002 on estrogen and bone density 7 and fractures was reviewed for this report. Fifteen of the trials included in the Cochrane review did not meet inclusion criteria for this review because they used ineligible estrogen 177-191 preparations. Results of the Cochrane meta-analysis included: • The pooled percent change in bone density was statistically significantly increased with estrogen compared to placebo at all measurement sites when combining results for all prevention and treatment trials and for both opposed and unopposed regimens. Hormone therapy Page 47 of 110 Final Report Update 3 Drug Effectiveness Review Project o For high-dose estrogen (equivalent to 0. For the lumbar spine, the differences between estrogen and placebo groups were: o 5. This study was restricted to placebo-controlled trials of at least 2 year’s duration and enrollment of at least 60 subjects. Although the study did not report a systematic assessment of the quality of the trials selected for review, the number of dropouts in each trial and use of intention-to-treat results were assessed. The 2-year mean changes in lumbar spine BMD (weighted for the ratio of sample size/dropouts) are summarized as follows: o 7. Fractures Head-to-head comparisons No head-to-head trials were found. Placebo comparisons We identified 11 studies of estrogen that included outcome data on fractures (Evidence 128, 135, 144, 155, 156, 168, 193 7 Table 6). Seven were included in a recent Cochrane meta-analysis, and 4, 117, 149, 194 the remainder were more recently published. Only one study of oral E2 evaluated fracture outcomes and found a statistically significant risk reduction for forearm fractures (RR=0. Both studies of transdermal E2 indicated no 128, 135 128 significant improvement in vertebral and non-vertebral fractures. One trial of E2V in early postmenopausal women reported a significant decrease in nonvertebral (RR=0. Although some of these studies showed a trend toward reduction of fractures at various sites in the treatment groups, only 4 the WHI showed a significant result. When compared with the placebo group, total fractures for 4 women on CEE were significantly reduced (HR=0. Risks were also reduced for site-specific fractures of the hip and vertebra, although confidence intervals adjusted for multiple comparisons included 1. This effect did not differ in women stratified by age, body mass index, smoking status, history of falls, personal and family history of fracture, total calcium intake, past use of hormone therapy, bone density, or summary fracture risk score. Hip fractures and clinical vertebral fractures were also decreased, although 95% confidence intervals adjusted for multiple comparisons overlapped a HR of 1. Additional data on fractures recorded 173 through the study termination (average 7. These positive effects occurred largely irrespective of baseline risk factors for osteoporosis or fracture. The global index of overall health risks and benefits was balanced, however, with no evidence of overall benefit or risk noted even for women in the highest tertile of risk for fracture. Comparison with Cochrane meta-analysis 128, 135, 144, 155, 156, 168, 193 Seven studies reporting fracture outcomes were included in a 7 Cochrane review published in 2002. Two trials indicating significant fracture risk reduction, including the WHI, were not included because they were published after the Cochrane 117 analysis. Findings included: • Four of five studies measuring vertebral fracture outcomes indicated non-statistically 131, 151 ,164, significant reductions in estrogen groups (RR=0. What is the comparative safety of different hormone therapy preparations for short-term use (<5 years)? Summary points - Breast tenderness and vaginal bleeding increase with all estrogen preparations. Hormone therapy Page 49 of 110 Final Report Update 3 Drug Effectiveness Review Project - All of the trials of symptoms and most of the trials of bone density and fractures were less than 5 years in duration and few enrolled more than 200 participants.